ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Takeda, Humanis Saglık Anonim Sirketi and Knoa Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Takeda×Humanis Saglık Anonim Sirketi×Knoa Pharma×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

TakedaHumanis Saglık Anonim SirketiKnoa Pharma
studies on the registry1,7544273
open to participants now8600
phase 3 studies under way4400
reach primary completion within a year4700
programswith a study of their own in two years25182

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseTakedaHumanis Saglık Anonim SirketiKnoa Pharma
Phase 1

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%

Humanis Saglık Anonim Sirketi: 18 of its 18 programs at phase 1

  1. Trijardy® XR Tabletsphase 1
  2. bempedoic acidphase 1
  3. Empagliflozin/Linagliptinphase 1
  4. selexipagphase 1
  5. Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)phase 1

and 13 more — sign in to see them all

100%

Knoa Pharma: 1 of its 2 programs at phase 1

  1. Magnesium Chloridephase 1
50%
Phase 2

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%
00%00%
Phase 3

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%
00%00%
Approved, new studies

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%
00%

Knoa Pharma: 1 of its 2 programs at approved, new studies

  1. nalmefeneapproved, new study
50%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
Humanis Saglık Anonim Sirketi0 readouts · 0 phase 3············
Knoa Pharma0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Humanis Saglık Anonim Sirketi

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Knoa Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionTakedaHumanis Saglık Anonim SirketiKnoa Pharma
Renal Insufficiencyall three · compare here

Takeda in Renal Insufficiency: 1 program

  1. teduglutidephase 3

Their studies: Takeda’s studies of Renal Insufficiency in search

Humanis Saglık Anonim Sirketi in Renal Insufficiency: 1 program

  1. ertugliflozinphase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Renal Insufficiency in search

Knoa Pharma in Renal Insufficiency: 1 program

  1. nalmefeneapproved, new study

Their studies: Knoa Pharma’s studies of Renal Insufficiency in search

Depressive Disorder, Major2 of 3 · compare here

Takeda in Depressive Disorder, Major: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Depressive Disorder, Major in search

Humanis Saglık Anonim Sirketi in Depressive Disorder, Major: 3 programs

  1. brexpiprazolephase 1
  2. cariprazinephase 1
  3. lisdexamfetaminephase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Depressive Disorder, Major in search

–
Heart Failure2 of 3 · compare here–

Knoa Pharma in Heart Failure: 1 program

  1. Magnesium Chloridephase 1

Their studies: Knoa Pharma’s studies of Heart Failure in search

Alzheimer Disease2 of 3 · compare here

Takeda in Alzheimer Disease: 1 program

  1. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Alzheimer Disease in search

Humanis Saglık Anonim Sirketi in Alzheimer Disease: 1 program

  1. brexpiprazolephase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Alzheimer Disease in search

–
Attention Deficit Disorder with Hyperactivity2 of 3 · compare here

Takeda in Attention Deficit Disorder with Hyperactivity: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Attention Deficit Disorder with Hyperactivity in search

Humanis Saglık Anonim Sirketi in Attention Deficit Disorder with Hyperactivity: 1 program

  1. lisdexamfetaminephase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Attention Deficit Disorder with Hyperactivity in search

–
Coronary Artery Disease2 of 3 · compare here–

Humanis Saglık Anonim Sirketi in Coronary Artery Disease: 1 program

  1. bempedoic acidphase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Coronary Artery Disease in search

Knoa Pharma in Coronary Artery Disease: 1 program

  1. Magnesium Chloridephase 1

Their studies: Knoa Pharma’s studies of Coronary Artery Disease in search

Depression2 of 3 · compare here

Takeda in Depression: 1 program

  1. Vortioxetineapproved, new study

Their studies: Takeda’s studies of Depression in search

Humanis Saglık Anonim Sirketi in Depression: 1 program

  1. cariprazinephase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Depression in search

–
Fatty Liver2 of 3 · compare here

Takeda in Fatty Liver: 1 program

  1. ontamalimabphase 3

Their studies: Takeda’s studies of Fatty Liver in search

Humanis Saglık Anonim Sirketi in Fatty Liver: 1 program

  1. ertugliflozinphase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Fatty Liver in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetTakedaHumanis Saglık Anonim SirketiKnoa Pharma
HTR1AVortioxetinerulebrexpiprazolerule–
A target, or a pathogen for a vaccine, known for: Takeda 12 of 25 · Humanis Saglık Anonim Sirketi 9 of 18 · Knoa Pharma 1 of 2 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.